Atox Bio is a clinical-stage biotechnology company based in Ness Ziona, Israel and Chapel Hill, NC, developing novel therapies for critically ill patients. The company is led by CEO Dan Teleman and is developing Reltecimod (AB103), a peptide that binds the CD28 co-stimulatory receptor to restore the host immune response to severe infections. Reltecimod is currently being studied in ACCUTE, a Phase 3 clinical trial in patients with Necrotizing Soft Tissue Infections (NSTI). Atox Bio plans to advance Reltecimod into Acute Kidney Injury (AKI) and intends to initiate a Phase 2 clinical study in that indication during 2018. Reltecimod has received Orphan Drug status from the FDA and EMA and holds Fast Track designation. The company raised $30M in financing to support these clinical programs. Atox Bio, based in Ness Ziona, Israel, develops immunomodulatory therapeutics for severe infections, notably AB103 for necrotizing soft tissue infections (NSTI). AB103 is a short peptide licensed from Yissum, discovered by Prof. Raymond Kaempfer and Dr. Gila Arad, that binds the CD28 dimer interface to modulate the host inflammatory response without inhibiting it. This host-targeting approach aims to avoid rapid drug resistance and provide broad-spectrum activity independent of pathogen type. AB103 completed a Phase 2 trial showing faster resolution of organ dysfunction, fewer ICU days, reduced need for assisted ventilation, and fewer surgical debridements. The product has FDA Fast Track and Orphan Drug designations and a positive opinion from the EMA’s COMP. The company recently secured financing to advance AB103 into late-stage clinical development beginning in the second half of 2015. Atox Bio is developing AB103, a rationally designed short peptide that acts as a CD28 modulator to regulate the host inflammatory response. AB103 is in Phase 2 clinical trials at seven leading U.S. surgical trauma centers for necrotizing soft tissue infections (NSTI). The FDA granted AB103 orphan drug designation in October 2011. The company raised $3.25 million in an initial closing and said proceeds will be used to advance the Phase 2 study and to expand into new therapeutic categories. A second closing was planned for early 2012. Atox Bio will be included as a portfolio company of Integra Holdings, a holding company formed by Yissum.

Total raised

$56M

Funding rounds

3

Latest round

Series F

Latest activity

Dec 2017